UroGen Pharma (NASDAQ:URGN) Receives Buy Rating from HC Wainwright

UroGen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They currently have a $54.00 price target on the stock. HC Wainwright’s price target indicates a potential upside of 301.49% from the stock’s current price.

Separately, Oppenheimer reduced their price objective on UroGen Pharma from $35.00 to $34.00 and set an “outperform” rating for the company in a research report on Friday, March 15th.

UroGen Pharma Stock Down 2.9 %

URGN stock opened at $13.45 on Monday. UroGen Pharma has a twelve month low of $8.69 and a twelve month high of $24.13. The business’s fifty day moving average is $15.12 and its 200-day moving average is $14.71. The company has a market cap of $315.40 million, a P/E ratio of -3.61 and a beta of 1.09.

UroGen Pharma (NASDAQ:URGN) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.05). The firm had revenue of $23.53 million for the quarter, compared to the consensus estimate of $22.30 million. Research analysts anticipate that UroGen Pharma will post -3.59 earnings per share for the current fiscal year.

Insider Activity at UroGen Pharma

In other UroGen Pharma news, insider Mark Schoenberg sold 12,000 shares of UroGen Pharma stock in a transaction on Monday, March 18th. The shares were sold at an average price of $14.05, for a total transaction of $168,600.00. Following the completion of the transaction, the insider now directly owns 139,437 shares of the company’s stock, valued at $1,959,089.85. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 11.13% of the stock is owned by company insiders.

Hedge Funds Weigh In On UroGen Pharma

A number of hedge funds have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC bought a new position in UroGen Pharma in the third quarter valued at about $53,000. China Universal Asset Management Co. Ltd. raised its position in UroGen Pharma by 361.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,575 shares of the company’s stock worth $54,000 after purchasing an additional 2,801 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of UroGen Pharma in the fourth quarter worth approximately $131,000. Federated Hermes Inc. acquired a new position in shares of UroGen Pharma in the 3rd quarter worth approximately $184,000. Finally, Sierra Summit Advisors LLC bought a new stake in UroGen Pharma during the fourth quarter valued at $218,000. Institutional investors own 91.29% of the company’s stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.